← Leaderboards
Jason Gertz
Hudson-Alpha Institute For Biotechnology
$6,280,882
Attributed
$6,912,823
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,714,704 · 10
By mechanism
R01$3,998,631 · 2
P01$3,198,503 · 2
R21$1,454,383 · 3
R00$810,951 · 1
K99$190,272 · 1
P30$61,964 · 1
Top collaborators
- Bradley R Cairns2 shared
- Chris Gregg1 shared
- Kimberly K Leslie1 shared
Most similar at Hudson-Alpha Institute For Biotechnology
Same institution · by research overlap
- Gregory Michael Cooper$12,802,939
- Richard M Myers$92,302,453
- Jesse N Cochran$1,321,606
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesGenomicsCellsGene Expression RegulationGenome-WideGene ExpressionEndometrial CarcinomaPlayRegulator GenesResponseGenomeEnhancersEstrogensEventGenetic TranscriptionBaseGeneticKnock-OutMediatingSignal TransductionProgramsMolecularCell TypeChromatin
Grant awards (23)
Advancing Hormone Therapy for Endometrial Cancer$2,801,881
P01 · FY2025 · CA
The combined role of ARID1A loss and estrogen signaling in endometrial cancer$422,270
R01 · FY2025 · CA · contact PI
Data Analysis Core$396,622
P01 · FY2025 · CA · contact PI
The combined role of ARID1A loss and estrogen signaling in endometrial cancer$422,237
R01 · FY2024 · CA · contact PI
Mechanisms of tamoxifen-associated endometrial cancer risk$170,988
R21 · FY2024 · CA · contact PI
Mechanisms of tamoxifen-associated endometrial cancer risk$215,869
R21 · FY2023 · CA · contact PI
In situ evaluation of combinatorial gene regulation in the human genome$654,613
R01 · FY2021 · HG · contact PI
In vivo multiplexed silencing of cis-elements in the brain$419,375
R21 · FY2021 · AG
Nuclear Control of Cell Growth and Differentiation (NC)$61,964
P30 · FY2021 · CA · contact PI
In situ evaluation of combinatorial gene regulation in the human genome$654,614
R01 · FY2020 · HG · contact PI
In situ evaluation of combinatorial gene regulation in the human genome$597,426
R01 · FY2019 · HG · contact PI
In situ evaluation of combinatorial gene regulation in the human genome$57,188
R01 · FY2019 · HG · contact PI
In situ evaluation of combinatorial gene regulation in the human genome$596,774
R01 · FY2018 · HG · contact PI
In situ evaluation of combinatorial gene regulation in the human genome$593,509
R01 · FY2017 · HG · contact PI
Development of Enhancer RNA-based Biomarkers in FFPE Tissue$226,853
R21 · FY2017 · CA · contact PI
Impact of enhancer sequence and interacting factors on estrogen receptor-mediated$296,508
R00 · FY2016 · HG · contact PI
Development of Enhancer RNA-based Biomarkers in FFPE Tissue$226,853
R21 · FY2016 · CA · contact PI
Impact of enhancer sequence and interacting factors on estrogen receptor-mediated$248,709
R00 · FY2015 · HG · contact PI
Development of Enhancer RNA-based Biomarkers in FFPE Tissue$194,445
R21 · FY2015 · CA · contact PI
Impact of enhancer sequence and interacting factors on estrogen receptor-mediated$17,451
R00 · FY2015 · HG · contact PI
Impact of enhancer sequence and interacting factors on estrogen receptor-mediated$248,283
R00 · FY2014 · HG · contact PI
Impact of enhancer sequence and interacting factors on estrogen receptor-mediated$95,136
K99 · FY2013 · HG · contact PI
Impact of enhancer sequence and interacting factors on estrogen receptor-mediated$95,136
K99 · FY2012 · HG · contact PI